Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

For all its imperfections at treating Parkinson's disease (PD), orally‐administered levodopa (l‐dopa) can be regarded as the “platinum” standard of PD therapeutics for its impact on disability and discomfort and its cost‐effectiveness. The past half‐century has confirmed that the typical l‐dopa...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 30; no. 1; pp. 64 - 72
Main Author: LeWitt, Peter A.
Format: Journal Article
Language:English
Published: United States Blackwell Publishing Ltd 01-01-2015
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For all its imperfections at treating Parkinson's disease (PD), orally‐administered levodopa (l‐dopa) can be regarded as the “platinum” standard of PD therapeutics for its impact on disability and discomfort and its cost‐effectiveness. The past half‐century has confirmed that the typical l‐dopa–treated patient gains improvement for most Parkinsonian features, presumably by conversion of this amino acid into dopamine in the striatum. However, fundamental questions remain as to its full mechanism of action and how adverse reactions evolve. Various aspects of clinical phenomenology associated with chronic l‐dopa use (such as dyskinesias and the long‐duration anti‐Parkinsonian response) present a continuing challenge for better understanding of its pharmacology. The pharmacokinetics of l‐dopa tend to predict some of problems that can emerge during chronic therapy, which can be linked with its irregular uptake and marked dose‐by‐dose variability in plasma concentrations. Several new pharmaceutical approaches are targeted at the unique physiology of l‐dopa uptake and are likely to improve the consistency of its anti‐Parkinsonian effect. © 2014 International Parkinson and Movement Disorder Society
Bibliography:ark:/67375/WNG-WFLMNPDC-H
ArticleID:MDS26082
istex:C2EEC2FFA4008A1B3FC5CD26D239EAA531DC0B17
Full financial disclosures and author roles may be found in the online version of this article.
Nothing to report.
Relevant conflicts of interest/financial disclosures
Funding agencies
This study was supported by a gift from MAC Valves Foundation.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.26082